Citius Oncology grants Mayersohn 125,000 stock options
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Citius Oncology, Inc. (CTOR) director Joel David Mayersohn received options covering 125,000 common shares on November 12, 2026, with an exercise price of $0.5223 per share. The award vests in full on November 12, 2027, subject to Continuous Service, and expires November 12, 2036. He reported 321,228 common shares, including 300,000 restricted stock units granted September 19, 2025, which vest in full on the third anniversary of that grant, subject to Continuous Service.
Insider Trade Summary
Grant/Award: 125,000 shares
Grant/Award
1 txn
Insider
Mayersohn Joel David
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) F2 | 125,000 | $0.00 | $0.00 |
| Holding | Stock Option (Right to Buy) F3 | -- | -- | -- |
| Holding | Common Stock F1 | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 375,000 options, with 250,000 underlying shares of Common Stock (Direct);
Common Stock — 321,228 shares (Direct)
Footnotes (3)
- F1. Includes restricted stock units granted on September 19, 2025, in the amount of 300,000 shares. The shares underlying the restricted stock units will vest in full on the third anniversary of the grant date, subject to the Reporting Person's Continuous Service to Citius Oncology, Inc. (the "Company") or a Related Entity (as defined in the award agreement) as of the applicable vesting date.
- F2. These options were granted on November 12, 2026. The options vest in full on November 12, 2027, subject to the Reporting Person's Continuous Service to the Company or a Related Entity (as defined in the award agreement) as of the applicable vesting date.
- F3. These options were granted on December 12, 2024. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the grant date, subject to the Reporting Person's Continuous Service to the Company or a Related Entity (as defined in the award agreement) as of the applicable vesting date.
Key Figures
New option award: 125,000 options
Exercise price: $0.5223 per share
Option expiration: November 12, 2036
+5 more
8 metrics
New option award
125,000 options
Granted November 12, 2026; covers 125,000 common shares.
Exercise price
$0.5223 per share
New option award granted November 12, 2026.
Option expiration
November 12, 2036
New option award.
Common shares reported
321,228 shares
Includes 300,000 restricted stock units.
Restricted stock units
300,000 shares
Granted September 19, 2025; vest in full on the third anniversary, subject to Continuous Service.
Existing options
250,000 underlying common shares
Direct option position reported; options vest in thirds on the one-, two- and three-year anniversaries of December 12, 2024.
Exercise price
$1.07 per share
Existing options expiring December 12, 2034.
Option expiration
December 12, 2034
Existing options covering 250,000 common shares.
Key Terms
restricted stock units, Continuous Service, exercise price
3 terms
restricted stock units financial
"shares underlying the restricted stock units will vest in full"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Continuous Service technical
"subject to the Reporting Person's Continuous Service"
exercise price financial
"conversion or exercise price of $0.5223"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What options did CTOR director Joel David Mayersohn receive?
Mayersohn received options covering 125,000 common shares on November 12, 2026, at an exercise price of $0.5223 per share. They vest in full on November 12, 2027, subject to Continuous Service, and expire November 12, 2036.
When do Joel David Mayersohn's existing CTOR options vest?
The existing options covering 250,000 common shares vest one-third on each of the one-, two- and three-year anniversaries of December 12, 2024, subject to Continuous Service. They have a $1.07 exercise price and expire December 12, 2034.
AI-generated analysis. How Rhea-AI works. Not financial advice.
